Chemours (NYSE:CC) Given New $22.00 Price Target at JPMorgan Chase & Co.

Chemours (NYSE:CC) had its target price boosted by analysts at JPMorgan Chase & Co. from $17.00 to $22.00 in a note issued to investors on Thursday,Benzinga reports. The firm currently has a “neutral” rating on the specialty chemicals company’s stock. JPMorgan Chase & Co.‘s price target indicates a potential upside of 2.32% from the company’s current price.

Other equities research analysts also recently issued reports about the stock. The Goldman Sachs Group lifted their price objective on shares of Chemours from $14.00 to $18.00 and gave the stock a “neutral” rating in a research note on Wednesday, February 25th. BMO Capital Markets lowered their price objective on shares of Chemours from $20.00 to $19.00 and set an “outperform” rating for the company in a research note on Monday, February 23rd. Alembic Global Advisors restated an “overweight” rating and set a $30.00 target price on shares of Chemours in a research report on Wednesday, May 13th. UBS Group boosted their target price on shares of Chemours from $29.00 to $30.00 and gave the company a “buy” rating in a research report on Friday, May 8th. Finally, Royal Bank Of Canada boosted their target price on shares of Chemours from $26.00 to $29.00 and gave the company an “outperform” rating in a research report on Monday, May 11th. Six analysts have rated the stock with a Buy rating, six have assigned a Hold rating and one has given a Sell rating to the company. Based on data from MarketBeat.com, Chemours currently has a consensus rating of “Hold” and an average target price of $23.55.

Chemours Stock Performance

Shares of NYSE:CC traded down $0.77 on Thursday, hitting $21.50. 2,537,990 shares of the company were exchanged, compared to its average volume of 3,335,669. Chemours has a 1-year low of $9.13 and a 1-year high of $28.67. The stock’s 50 day moving average price is $22.29 and its 200 day moving average price is $17.25. The company has a current ratio of 1.82, a quick ratio of 0.87 and a debt-to-equity ratio of 18.98. The firm has a market capitalization of $3.23 billion, a P/E ratio of -8.13 and a beta of 1.47.

Chemours (NYSE:CC) last posted its quarterly earnings data on Tuesday, May 5th. The specialty chemicals company reported $0.05 EPS for the quarter, topping the consensus estimate of ($0.05) by $0.10. Chemours had a negative net margin of 6.82% and a positive return on equity of 52.49%. The business had revenue of $1.38 billion during the quarter, compared to the consensus estimate of $1.40 billion. During the same period in the previous year, the firm posted $0.13 earnings per share. The business’s revenue for the quarter was up 1.0% compared to the same quarter last year. Sell-side analysts predict that Chemours will post 1.27 EPS for the current year.

Institutional Inflows and Outflows

Institutional investors and hedge funds have recently added to or reduced their stakes in the business. Y Intercept Hong Kong Ltd purchased a new position in Chemours in the third quarter valued at $2,124,000. WINTON GROUP Ltd raised its position in shares of Chemours by 103.5% in the third quarter. WINTON GROUP Ltd now owns 114,100 shares of the specialty chemicals company’s stock worth $1,807,000 after acquiring an additional 58,039 shares during the period. Hudson Bay Capital Management LP acquired a new position in shares of Chemours in the third quarter worth about $1,925,000. SG Americas Securities LLC raised its position in shares of Chemours by 478.4% in the fourth quarter. SG Americas Securities LLC now owns 236,236 shares of the specialty chemicals company’s stock worth $2,785,000 after acquiring an additional 195,393 shares during the period. Finally, Wolf Hill Capital Management LP acquired a new position in shares of Chemours in the third quarter worth about $17,025,000. 76.26% of the stock is currently owned by institutional investors and hedge funds.

Key Stories Impacting Chemours

Here are the key news stories impacting Chemours this week:

• Negative Sentiment: Zacks Research sharply reduced Chemours’ Q2 2026 EPS estimate to $0.33 from $0.60, signaling weaker near-term earnings expectations.
• Negative Sentiment: The firm also cut FY2026 EPS to $0.90 from $1.06 and lowered FY2027 EPS slightly, reinforcing concerns about the company’s earnings trajectory.
• Negative Sentiment: Additional downgrades to Q1 2027, Q2 2027, Q3 2026, and Q4 2026 earnings estimates suggest analysts see continued margin or demand pressure in the next few quarters.
• Neutral Sentiment: Zacks Research kept its Hold rating on Chemours, indicating analysts are not turning bullish despite some longer-term estimate increases for 2027 and 2028.
• Positive Sentiment: Some longer-dated estimates were nudged higher, including Q4 2027 and Q3 2027 EPS, which suggests analysts still see a possible earnings recovery over time.

Chemours Company Profile

Chemours Company, established in 2015 as a spin-off from E. I. du Pont de Nemours and Company, is a global chemistry organization headquartered in Wilmington, Delaware. Since its formation, Chemours has focused on delivering performance chemicals that help customers lower their carbon footprint, increase energy efficiency and conserve water. The company operates with a commitment to safety, environmental stewardship and innovation.

Chemours’ principal business activities are organized into three core segments.